-- 周四下午,能源股上涨,纽约证券交易所能源板块指数上涨1%,道富能源精选板块SPDR ETF(XLE)上涨0.8%。 费城石油服务板块指数上涨0.5%,道琼斯美国公用事业指数上涨1.3%。 西德克萨斯中质原油下跌2.4%,至每桶104.37美元;全球基准布伦特原油下跌3.5%,至每桶113.93美元。亨利枢纽天然气期货上涨4%,至每百万英热单位2.75美元。 行业新闻方面,截至4月24日当周,美国天然气库存增加790亿立方英尺,低于彭博社调查预期的830亿立方英尺增幅,而前一周的增幅为1030亿立方英尺。 企业新闻方面,据路透社报道,阿波罗全球管理公司 (APO)、黑石集团 (BX) 和 KKR 集团 (KKR) 已进入壳牌公司 (SHEL) 加拿大液化天然气项目主要股权的最终竞标阶段,该交易金额可能超过 100 亿美元,最高可达 150 亿美元。壳牌股价上涨 1.2%。 道达尔能源公司 (TTE) 和合作伙伴 Nextnorth 宣布,已完成融资,并在菲律宾伊拉甘破土动工兴建一座 440 兆瓦峰值功率的太阳能发电厂。道达尔能源股价上涨 1.4%。 据彭博社报道,英国石油公司 (BP) 已与委内瑞拉签署协议,共同勘探海上天然气。今年 1 月美国逮捕尼古拉斯·马杜罗后,委内瑞拉能源行业发展势头强劲。英国石油公司股价上涨 1.1%。
Related Articles
Sector Update: Financial
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%